142 related articles for article (PubMed ID: 16794359)
1. Currently available somatostatin analogs are not good for Graves' orbitopathy.
Tanda ML; Bartalena L
J Endocrinol Invest; 2006 May; 29(5):389-90. PubMed ID: 16794359
[No Abstract] [Full Text] [Related]
2. Novel treatment modalities for Graves' orbitopathy.
Bartalena L; Lai A; Sassi L; Lombardi V; Dalle Mule I; Gandolfo M; Liparulo L; Azzolini C; Piantanida E; Tanda ML
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():210-6. PubMed ID: 20467365
[TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy.
Stan MN; Garrity JA; Bradley EA; Woog JJ; Bahn MM; Brennan MD; Bryant SC; Achenbach SJ; Bahn RS
J Clin Endocrinol Metab; 2006 Dec; 91(12):4817-24. PubMed ID: 16984988
[TBL] [Abstract][Full Text] [Related]
4. [Somatostatin analogue treatment in Graves' ophthalmopathy: a case report].
Coloma-González I; Mengual-Verdú E; Domínguez-Escribano JR; Hueso-Abancens JR
Arch Soc Esp Oftalmol; 2007 Jan; 82(1):51-4. PubMed ID: 17262238
[TBL] [Abstract][Full Text] [Related]
5. [Somatostatin analogs].
Krysiak R; Okopień B; Herman ZS
Pol Arch Med Wewn; 2006 Oct; 116(4):988-97. PubMed ID: 18416302
[No Abstract] [Full Text] [Related]
6. [Octreotide scintigraphy in thyroid orbitopathy].
Aguirre-Balsalobre F; Mengual-Verdú E; Muñoz-Acosta JM; Martínez-Caballero A; Caballero-Carpena O; Hueso-Abacens JR
Arch Soc Esp Oftalmol; 2007 Mar; 82(3):133-9. PubMed ID: 17357889
[TBL] [Abstract][Full Text] [Related]
7. Somatostatin analogs for Graves' ophthalmopathy: do they bounce off like a rubber bullet?
Bartalena L; Marcocci C; Pinchera A
J Clin Endocrinol Metab; 2004 Dec; 89(12):5908-9. PubMed ID: 15579734
[No Abstract] [Full Text] [Related]
8. Thyroid-associated ophthalmopathy in juvenile Graves' disease--clinical, endocrine and therapeutic aspects.
Krassas GE; Gogakos A
J Pediatr Endocrinol Metab; 2006 Oct; 19(10):1193-206. PubMed ID: 17172081
[TBL] [Abstract][Full Text] [Related]
9. Slow-release lanreotide in Graves' ophthalmopathy: A double-blind randomized, placebo-controlled clinical trial.
Chang TC; Liao SL
J Endocrinol Invest; 2006 May; 29(5):413-22. PubMed ID: 16794364
[TBL] [Abstract][Full Text] [Related]
10. The role of somatostatin analogs in the management of Graves' ophthalmopathy.
Bartalena L; Tanda ML; Piantanida E; Lai A
J Endocrinol Invest; 2003; 26(8 Suppl):109-13. PubMed ID: 15233224
[No Abstract] [Full Text] [Related]
11. Corticosteroids in the medical treatment of thyroid ophthalmopathy: when and how? Somatostatin analogues: where we stand today.
Krassas GE; Gogakos A; Boboridis K
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():204-9. PubMed ID: 20467364
[TBL] [Abstract][Full Text] [Related]
12. Modulation of expression of somatostatin receptor subtypes in Graves' ophthalmopathy orbits: relevance to novel analogs.
Cozma I; Zhang L; Uddin J; Lane C; Rees A; Ludgate M
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1630-5. PubMed ID: 17848636
[TBL] [Abstract][Full Text] [Related]
13. Advances in the pharmacological treatment of Graves' orbitopathy.
Ruchała M; Sawicka-Gutaj N
Expert Rev Clin Pharmacol; 2016 Jul; 9(7):981-9. PubMed ID: 26966785
[TBL] [Abstract][Full Text] [Related]
14. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.
Wémeau JL; Caron P; Beckers A; Rohmer V; Orgiazzi J; Borson-Chazot F; Nocaudie M; Perimenis P; Bisot-Locard S; Bourdeix I; Dejager S
J Clin Endocrinol Metab; 2005 Feb; 90(2):841-8. PubMed ID: 15562016
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for Graves' ophthalmopathy.
Salvi M
Curr Opin Endocrinol Diabetes Obes; 2014 Oct; 21(5):409-14. PubMed ID: 25105999
[TBL] [Abstract][Full Text] [Related]
16. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy.
Krassas GE
J Endocrinol Invest; 2004 Mar; 27(3):281-7. PubMed ID: 15165005
[TBL] [Abstract][Full Text] [Related]
18. [Could delayed action flanreotide be used as substitute for octreotide in the treatment of dumping syndrome?].
Bouché O; Salmon-Ettersperger L; Frémond L; Thiéfin G; Zeitoun P
Gastroenterol Clin Biol; 1997; 21(1):84-5. PubMed ID: 9091398
[No Abstract] [Full Text] [Related]
19. Therapy of Graves' ophthalmopathy: a novel application of somatostatin analogues.
Díez JJ
Expert Opin Pharmacother; 2001 Sep; 2(9):1361-5. PubMed ID: 11585016
[No Abstract] [Full Text] [Related]
20. Neuroimaging of Graves' orbitopathy.
Müller-Forell W; Kahaly GJ
Best Pract Res Clin Endocrinol Metab; 2012 Jun; 26(3):259-71. PubMed ID: 22632363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
